With that, I would like to welcome Will Lewis, the CEO of Insmed. Thank you very much for joining us today.
Thanks for having me here.
All right, great. Maybe if we could start off, we are almost a year out, or a little over a year from the approval of BRINSUPRI. I was hoping you can just step back, give us some key takeaways, learnings, anything that you would glean as important from the launch so far.
Yeah. Well, I will just start out by saying this launch has blown away all our expectations. We started out, I remember vividly describing that we were going to use a basket of other specialty respiratory launches to help benchmark whether or not we thought the launch was going well, and we took from that basket of best performers a first-year revenue production of about $500 million-$700 million. And at the time, I got a lot of heat for that because people thought, "Well, why would you set yourself against the best launches out there?
You might not be able to achieve that, and you would set yourself on your back heel. Today, as you know, we sit with an estimate for the first full year of $1.25 billion to $1.4 billion, which is just staggering, and it now places us on track to be one of the top 20 commercial launches of all time in any therapeutic category. So by all measures, this launch has outperformed. The team has just done an exceptional job, and I think that bodes well for the future. What we've learned from that, a number of things, actually. I think we know that this is now a highly promotion-sensitive drug. That doesn't surprise us. That's what we expected.
But to see that now play out with a year under our belt, we have really good understanding of how we can activate patient and physician interest, what channels through a media perspective are most effective and most efficient. W e can pull those levers to the extent that we need to help re-energize certain parts of the country as we move forward. But we've just upped our guidance. We think peak sales for this drug will be north of $7 billion , and that does not include any contribution from the COPD or asthma comorbid populations. So this is going to be a very, very big drug, and we're super excited about the success that the team has produced to date.
Great. So what were you seeing in the launch that supported the raise in guidance? Any key elements or things that really supported getting to the point and going above $1 billion at the end of the year?
Yeah. Well, we gathered more confidence in our own commercial effectiveness estimates. We obviously have an extensive dashboard that we track every little metric within the launch very carefully. S hout-out to the commercial effectiveness team. We've now tracked along those metrics. We're either at or ahead of pretty much every one of them across the board since launch. T hat gives us not only confidence that that team is doing an exceptional job, but it allows us to lean into the forward forecast where they think we're going to go. T hat's why we had this guidance raise in terms of both the target for the year and the overall peak sales estimate. Th e peak sales estimate, just to comment about that because I've gotten a number of questions about it.
We upped that guidance in August because every year in August, we not only have a board meeting and an earnings call, but we take about a day and a half for a strategic offsite with the board where we do a 10-year forward view. What do we think is going on with the company? Where are we going? Big-picture stuff. To inform that discussion, we go back and we redo all of our market access, all of our forecasting with the latest data. Since we had shared that with the board and it was very clear that our TPIP estimates were out of date, BRINSUPRI was stronger than expected, it was time to update, and we thought that was appropriate.
Should we anchor to August next year when you meet with the board for potential updates?
You know I knew that that was going to come back to haunt me to provide that level of clarity. No, August is always a good time to ask us how we're feeling about things, as is the beginning of the year. Those are natural break points for us. As and when we get information and get a real sense of clarity and conviction, that's when you can expect us to update.
Okay. That's fair. Now, drilling down a bit on the prescriber base, what percentage of current physician base is still trialing BRINSUPRI, maybe prescribing less than five patients? What does the timeline look do you think to convert these to higher prescribers?
I think what's exciting about this is that we have gotten such strong performance as I just was reviewing in terms of revenue generation. The breadth and depth have been very good. We still see opportunity, though, both for breadth and depth of prescribing behavior. There are literally more than 25,000 physicians we call on for BRINSUPRI prescription writing. Of those, it is a small fraction that have actually written one or more prescriptions. There are some that have written none. There are some that have written a handful and are, as you say, trialists. Then there are some who are higher prescribers. What is the breakdown? We are not giving the exact percentages, but what I would say is if you were involved in the clinical trial and you know the drug, you are much more inclined to write and write in large volume. That is not surprising.
What we are trying to do is spread that knowledge and that experience base across the balance of physicians that we have reached. Those who are trialing are now hearing back from patients, and as a result of that positive feedback loop, are writing more. Those who have never written before are hearing through speaker bureaus or events that they attend at American Thoracic Society meeting or the upcoming CHEST meeting about the progress with the drug. The bottom line here is the message across the board is very positive. We have tens of thousands of patients who have now taken the drug. We have many physicians, thousands of them, that have written the drug. If you want to think about this as a log-normal distribution, there is a huge bolus of physicians that are now able to be aware that everyone around them is writing this prescription.
The revenue just blows away every other launch that has been out there. All of this inures benefit to the perception of the launch as being strong. No new yellow flags in terms of side effect profiles. I think things only continue to be strong from here. I feel very, very good about where we are and where we are going.
From a payer perspective, everything on track, if not exceeding?
Yeah, I would say once again, another point of strength in this launch has been the market access picture. I give a strong shout-out to the market access team at Insmed. We identified this very early and resourced it accordingly, and consequently, the success rate. At one time, we were reporting north of 90% approval. We haven't updated that number, but I can just tell you that it continues to outstrip all benchmarks that are out there. We feel very good about market access. I don't anticipate that changing between now and the end of the year such that our gross-to-net update, which was 25% to low 20s, low high 20s, will remain that way, we think, for the rest of the year. That just speaks to the fact that this is now a steady cadence, and I think that is a message I would leave you with.
When you think about BRINSUPRI, we are now past the first year of launch. We know the trajectory of the launch. We know it's strong, and we expect it to continue to be strong. We'll just have to see how things go. I would just emphasize variability quarter to quarter a little bit is not the driving factor in whether or not this is going well. The main force that will influence this company's next trajectory is whether or not we're able to secure the COPD or asthma comorbid patient populations into the top of the funnel for this medicine. When we talk about our estimate of the total addressable market for BRINSUPRI, patients with bronchiectasis in the U.S., that estimate three years ago was around 500,000 patients. That grows every year. It grows because of patient population growth, 4%, whatever number you want to use.
It grows because these patients do not succumb from this disease. They're around longer, so the incidence population every year gets added to the prevalence population. It doesn't replace those that die off, and that means that the pie keeps getting bigger. In addition, there are patients who have one or fewer exacerbations who now have two or more because people are more sensitive to them, we're tracking them more accurately. So all these things in their benefit to growing that initial TAM. Having said that, when we talk about COPD or asthma comorbid population patients, let me try and put some numbers that will ground this. It's 500,000 patients we estimated as the original TAM. There are 32 million asthma and COPD patients in the U.S. alone. Of that group, some population also are comorbid with bronchiectasis.
We would guess that that may be in the 10%-20% range if you include asthma and COPD. So that is literally millions of additional potential patients. Now, how many of those are going to come into the top of the funnel? We think it's the moderate to severe patients, and we think it's those with two or more exacerbations. We know those patients are out there. We need to identify them and get them channeled into the top of the funnel because they will benefit from this medicine and they will be on label, and there are no additional clinical studies we need to pursue that. That presents an enormous opportunity to us because, as I said before, that $7 billion peak sales number does not include any of those patients.
The future will be focused on that, almost like a second launch within the company and bringing them into reach for treating physicians where these patients can benefit is going to be a major driving force in our future.
I think we ran a survey earlier in the year with pulmonologists. They said, I think around 16%-20% of their COPD or asthma patients could be comorbid bronchiectasis patients, and I believe 38% of their bronchiectasis patients were previously diagnosed with COPD or asthma. I guess, what are you focused on to change the prescribing dynamic, educating physicians, and when should we start to see this play out in the revenue numbers?
Yeah, I don't think we're going to. This is turning an oil tanker, right? This is a big group of patients, and we need to get the right ones into the right channel. I would expect that we will have data, because this is all looking back in hindsight, till probably the middle of next year, where we'll be able to have at least six months looking back. Are COPD patients being diagnosed with bronchiectasis at an increasing level? What's the degree of use of high-resolution CT scans in COPD patients? The work we're doing right now with the COPD Foundation across nearly a dozen centers in the U.S. to find out how many of the patients who have COPD and have CT scans actually also already had bronchiectasis, but it just wasn't diagnosed. We think that number could be in the 20% range.
That data will be available in the middle of next year, and it'll do two things. It'll quantify how many patients are out there with actual bronchiectasis that also have COPD. That'll allow us to extrapolate. It'll also change the rules at hospitals so that when they're doing high-res CT scans of COPD patients, they will automatically look for bronchiectasis, and that should also help channel into the right places whether or not these patients should be considered for treatment. Separately from the bronchiectasis patients, the COPD patients who are comorbid, we are also bringing forward another DPP-1 inhibitor that's entering phase I as we speak, looking at COPD patients who have more of an emphysema type phenotype that may benefit from DPP-1 inhibition who are not bronchiectasis patients.
There are slices of the COPD population that we intend to reach and hopefully provide benefit to from a couple of different angles.
Okay. I will ask a couple questions in a bit on that. But overall, in regards to potential seasonality, what you are seeing in the launch currently, because this is pretty much the first full year we are going through. Any comments you have there?
Well, there has been a lot of questions about whether we are seeing seasonality, and of course, we will not know until we are through the season. We will look back and we will say, "Okay, what happened in the summer? What happened in the fall? Did we see a changeover so that there is more evidence of patient need because of exacerbation increases or what have you?" It may be as simple as people were on vacation in the summer, doctors, patients, therapeutic specialists at Insmed. It could be any one number of these combinations that might have some influence on it. But I want to be really clear, I continue to feel like this launch is going extremely well. We do not see the weakness that sometimes people associate with the concept of seasonality. It is not that.
Is there additional upside either now or in the fall or next year during this time that we can think differently about accessing for the benefit of patients?
I imagine everyone's tracking scripts as we are. Are you still confident in the capture rates? I think we've noticed an acceleration over the last several weeks in regards to scripts. Any commentary around that?
Yeah. I think we've said repeatedly that the Symphony data that is out there, TRx data continues to be proportionately accurate as an estimate of what we are seeing. That should help reduce the volatility of what the quarter will look like. I would also say that the inherent variability of a launch, which can come from a dozen different sources, shouldn't end up driving an interpretation of how strong this launch is going. We've had quarter after quarter of incredibly strong performance. I'm not $5 million smart one direction or the other, and I wouldn't read it as a positive if it's above or a negative if it's below. We are on a trajectory to produce a mega blockbuster performance here, and that's where our eyes are focused.
Okay. Just going back briefly, next year, we'll all be interested in commentary around the COPD, asthma, comorbid bronchiectasis patient population. How should we expect the team to communicate that? Are we expecting an inflection? I don't think you're going to break out these patients who are comorbid.
No. What we will be looking at is some of these metrics like high-res CT scan rates, diagnosis rates among COPD subpopulations. We have a whole dashboard, as you might imagine, that we're trying to track. A lot of that is backward-looking, so we need to see what are the ICD-10 codes, how those evolved. What are we seeing from the data where we're doing this dozen-center study across the U.S.? What is the percentage of patients who have COPD today that also have bronchiectasis that wasn't previously captured? I think that's going to be quite high. So all of those things will inform whether or not those patients are there and to what degree are we able to access them and bring them into the top of the funnel, as it were. I think we have a pretty good shot at that. We've already made some good inroads.
If you think about what we did at the World Bronchiectasis Conference this year in Germany, we hosted 20 COPD key opinion leaders who came in, not for the bronchiectasis conference, but just to talk about COPD, bronchiectasis comorbidity and how they see that as an issue and what they might endeavor to do about it. We look at that as one point of success. The study that I mentioned before, I think there were the guidelines that were updated this summer. That is quite important, the GOLD guidelines that include highlighting for patients who have COPD, for example, that are on max dose treatments and are still experiencing exacerbations. Those patients should have a high-res CT scan and determine whether they have bronchiectasis. In the guidelines, it says, if they do, you should consider BRINSUPRI, our drug.
I think we are making early inroads, but they are important, and they will hopefully continue to support the strength of the launch as we go forward. As we get to next year, I call out the middle of the year as an approximate timeframe. We do not really know when we are going to see clear signs, but my guess is by then we should be seeing some breadcrumbs, if not actual numerical impact.
Okay. With all successful launches, especially when there is no real standard of care, you attract competition or copycats. Can you comment on that? How should we think about that longer term, or are there any risks to copycats?
Well, we fully expect our estimate of $7 billion plus in peak sales assumes that the next closest DPP-1 competitor is not only successful and approved, but that they will take meaningful market share from us. Moreover, it assumes that in 2035 we will face price renegotiation from IRA. Despite all of that overpressure, we still think we will do north of $7 billion comfortably. That opens up a whole window of opportunity when we think if either of those is different and/or if we are able to capture the COPD or asthma comorbid populations.
Okay. Before moving on to the second generation DPP-1s, could you just talk about briefly the Japanese opportunity, and thoughts on Europe after then?
Yeah. International generally for a launch like this is never usually more than about 10% or 15% of overall global revenue. Within that, we think the bulk of that is going to come from Japan. We do not yet have our final price from Japan, but certainly our interactions with the country so far have been very productive and positive. My expectation is that that will go well enough that we will be able to launch aggressively over there. I think the team is certainly ready to run through walls. I was just over there for the launch meeting, and it is a launch meeting not just for BRINSUPRI, but for the expanded label for ARIKAYCE. So we are sitting over there now with roughly 75 sales reps. We are going to add another 50 in the next year because the opportunity is significant enough.
I am super excited about what that will yield for that part of the world and its contribution to our overall performance. Japan has been a point of real strength in this company for a long time. There is just some excellent leadership and capability out there that we have been fortunate enough to be able to work with.
We are ruling out EU at the moment based on MFN or any comments there?
Yeah, I think EU we continue to have in a kind of a hold pattern. We're looking for clarity around reimbursability of the drug, and that is really the main driver. People often talk about other issues like MFN and the impact of that from that initial point. But the real issue is whether or not Europe is in a place where it can reimburse this drug at a level that would allow us to support an infrastructure over there. That's the question that needs to be asked and answered.
The price in Japan, we should get that by the end of the year?
Yes.
Okay. Any comments around expectations there? Fairly close to the U.S. price?
Well, yeah, I wouldn't want to comment it on that way. I guess what I would say through the lens of MFN and the risk that people sometimes see there, we're hopeful that a GDP-adjusted price coming out of Japan would be adequate to insulate us from any MFN risk. Of course, MFN is a moving target, and we don't really know what that's going to finally look like. For right now, I would say the vast majority of the revenue is going to come from the U.S. market. That is going extremely well. Japan is set to do a very solid performance. Having just come from there, I can tell you the enthusiasm is extremely high, as is the quality of the team.
Okay, great. Maybe let's move on to the future. DPP-1, second generation. You recently announced that INS1033 cleared IND in RA with UC and COPD to follow. Can you just walk us through your rationale, why you chose these indications, and when potentially we can learn more about this opportunity?
Sure. Well, our standard for any drug moving forward at Insmed is that it will be first or best in class in its respective disease state. For all three of those, DPP-1 is a novel mechanism of action and approach for contribution to those diseases. Some of them already have approved medicines. We would see this as a complement, not a replacement for most. This would be positioned as a combination therapy in those settings. As we think about the probability of success, historically, people are aware that we looked at DPP-1 and specifically BRINSUPRI in CRS without nasal polyps and hidradenitis suppurativa. In phase II, both of those failed to have statistical significance on their primary endpoints. You have to remember, though, that in both cases, those were biologically plausible opportunities. They were not backed by preclinical animal models.
What we have done for these three indications is that we have animal models for all three. We've tested not only this new next-generation drug, but also BRINSUPRI to index off of one another and their relative performance and capability. So we're very excited about these three. Glad to be in the clinic now and heading toward producing data next year for the profile that will emerge from phase I with this drug. Alongside that, we have other stuff coming out of research, but each of these is obviously a very substantial market. If we can make an inroad there, I think that's going to be very meaningful.
Yes, very much so. Maybe pivoting now to TPIP. You also raised peak sales estimates there. Can you walk us through the rationale? Which indications, I guess you're not going to break out the share for each indication, but any color would be great.
Sure. Remember that TPIP, when we had said the guidance for peak sales was $2 billion or greater, that was based on two indications, not four, and it was done before we had produced phase II data. Our phase II data was extremely strong, and very recently we just put out open label data that went out a year that was even stronger. What this does is it lays the groundwork for this drug to play a pivotal role in this disease state. All four of these disease states, I should say, IPF, PPF, PAH, and PH-ILD. When we think about each of those, know that we have data for treprostinil in three of four of them, and we are highly confident that this will be effective.
When we think about the degree of impact our drug has had, it blows away any other prostanoid that has produced data for these indications. Materially better on all fronts. Convenience for patient, clinical efficacy, safety. We think it's second to none, and we think that the KOL community in PAH and PH-ILD specifically, have been extremely vocal in telling us about that. From that point of view, we took that new data, went out and did market research, and reached the conclusion that the greater than $2 billion estimate for peak sales for two indications with the new data was way outdated. We're now north of $6 billion for the four indications, and I would say proportionally, PH-ILD is a bigger indication than PAH, and PPF is a bigger indication than IPF. Each is a blockbuster. I wouldn't go in any more refined estimate than that.
But certainly this is the beginning of what we think is going to be the next chapter of growth for Insmed, and it's what makes us really distinct as a mid-cap company. Today we sit approaching with our current estimates by the end of the year, what would be almost $2 billion in revenue. From here, while we can't give a perfect estimate of the future, we're talking about very substantial year-over-year compound annual growth, both on the top and bottom line for the next five to 10 years, supported by ARIKAYCE and its label expansion, BRINSUPRI and the success of its launch, TPIP in four different indications, and that's without even tapping into what we've described by way of the COPD and asthma comorbid populations or anything from our pipeline.
If those things start to manifest in years five through 10, as we would expect, we're going to a whole other level.
Okay. Could you just outline for us where the TPIP trials stand, how enrollment is going, when we could potentially expect data?
We haven't given any guidance on timing for data. PH-ILD started first, and I would tell you that that is doing very well. PAH is now also underway. We expect PPF to kick off its phase III program by the end of this year and IPF at the beginning of next year. For each of these trials, one of the distinctions of this compound and its formulation is that we can go much, much higher in dosage than any other prostanoid. We can go all the way to 1,280 micrograms, and indeed that is set as the upper bound limit for patients to take or be guided to by their treating physician, which is materially more than any other prostanoid out there.
We should be able to gain greater efficacy and sustain that greater efficacy over time as patients often experience a waning effect from prostanoids as the receptor sensitivity changes. We can continue to titrate up and maintain that effect without needing to go to parenteral treatment. Which is a big advantage for patients and physicians.
Without having to comment specifically on the competitive landscape, are there readouts that you're watching closely or launches that really feed into your expectations for TPIP?
I have no problem calling out a success when it hits. There was a recent drug out of Roivant that just put up a very impressive phase II data. It's a different mechanism of action in the PH-ILD space. Congratulations to Matt and the team. That's a great drug, it looks like. We have to see phase III. I think our drug is every bit as good. Remember that we measured ours at 24 hours after administration of the drug, so it's at trough levels. Everybody in this industry, and particularly in this disease state, measures at peak levels. We're going to be adding that to our phase III data set, so it'll be interesting to see where our best data comes out at the end of the phase III trials. Look, the opportunity here for the arrival of these new technologies is profound.
These are fatal diseases for patients with a high mortality rate within five years. Our open label data from phase II showed that we could improve mortality using various measures in these patients with PAH. That's a game changer. We moved a huge percentage of patients down to class 1, which means that they are asymptomatic for this fatal disease. So the improvements we can bring, we've documented. If these other drugs and their metrics suggest that they are going to be impactful as well, then we're going to start having a discussion about combination therapy because we will be the prostanoid of choice. We're once a day with great efficacy and safety.
If they are once a day, also with an inhaled formulation, and they can bring great efficacy and safety as well, we may be able to change the paradigm and the expectations for this disease for patients, and that's what this is really all about. That would have the added benefit of keeping these patients alive for much longer, and therefore they would be taking the drug much longer to accomplish that, and that's the goal of the medicine. I see a very bright day forming on the horizon for PAH and PH-ILD patients in particular, and I'm hopeful that'll carry through to IPF and PPF as well.
Okay. In the last eight minutes or so, maybe briefly touching on your gene therapy efforts, DMD, ALS, when can we expect an update there? How are things going in the trials?
Yeah. So we have several platforms that we sort of went out and acquired about four years ago, and I'll just review so people understand. Expanded the efforts that are underway in New Jersey for DPP-1 and related therapies. Acquired what's called synthetic rescue capability in Cambridge, England. De-immunized therapeutic proteins using artificial intelligence for design of B and T cell epitope deletion in New Hampshire, and gene therapy using viral vectors targeting monogenic diseases out of San Diego. Each of these has been running quietly in parallel and making great progress over the last four years. Next year heralds the arrival of the first data from these different component parts. Understandably, this has not been the focus of Wall Street because we've had so much going on, and at such scale, with our other respiratory portfolio.
But it's important to understand that the answer to the question of what's next in our portfolio is already well in hand at Insmed. We don't need to go out and do some dramatic BD deal to sort of add a new leg of excitement to the company. I'm not ruling out that we wouldn't consider BD, but I want to just be clear, we're in an enviable position of not needing to force that decision kind of matrix. When we look at what we have in hand, we have DMD and ALS that are well underway in terms of clinical trial work and data collection. Our intention when we put out this data next year is to identify whether or not they clear the threshold of first or best-in-class therapies for these diseases.
If indeed they do, you can expect a robust data presentation, which will include a mosaic of measures to ensure that people know that it is not cherry-picking one point or another from the backdrop of how you improve a DMD patient. It will be dystrophin expression, transduction efficiency, safety, and NSAA impact on patient actual physical performance. That mosaic will tell a strong picture, we hope, for the impact of our approach in Duchenne muscular dystrophy gene therapy. In addition, ALS, we're going to have some very good data, we hope, by the middle of next year, that will document whether this is effective not just in SOD1 mutation patients, which is a small portion of the population, but also sporadic patients, which is We are looking at other indications.
Out of New Hampshire, we have Uricase and IgG protease, both of which are being developed as de-immunized therapeutic proteins so that we can treat patients that are unable to take those medicines currently because of the immune system response. In the U.S. in New Jersey, we have a program for a pathway I'm not going to identify right now, but we are very excited about, which we think represents the answer to the patent cliff already formed by the success of BRINSUPRI. We go to 2039 on our patent protection with BRINSUPRI. We have identified, we think, a novel mechanism that could result in a medicine we could combine with BRINSUPRI so that we continue to own better efficacy for this population well past the 2039 mark, hopefully for a full patent extension into the 2050s.
We're a long way from that, but in the next 3- 5 years, we'll have the answer to that question, and it is the kind of thing that I think could really represent an inflection point in our value.
Okay, great. Maybe if we move on to a couple macro questions in the last couple of minutes we have. How is the rise of China innovation changing your competitive positioning and your R&D or maybe BD playbook?
Yeah. I think, China's arrival is here. Anybody who is still doubting or thinking that China is not a major player has been asleep at the switch. What they represent is best in class earliest stage development. So right now from concept through to commercialization is the spectrum of development. They're really good at getting through to proof of concept. There are a variety of reasons for that, but it's something that we can look at and study, A, hopefully to improve our own capabilities here in this country, but B, as a company, for the fastest way to validate that what we are developing is really going to make a difference. I think that's the first and best use of our time in terms of interacting with China right now.
We are examining novel molecules that are coming out of there that could represent interesting opportunities for us, as are many other companies. You do see a lot of copycat still coming out of there. There are DPP-1s that are being developed in China. They're way back in the line relative to where we are and where the next most powerful competitor is. That doesn't bother us at all. We welcome the competition. We think we've got the best-in-class molecule. We don't think that's going to change. But China's arrival presents both opportunities and additional competitive pressure.
Okay. Two last questions from me. We got to touch on AI. Insmed, are they leading the way in AI? How are you embracing it?
We are very much leaning into the use of AI in every corner of our company. Last night I was having a conversation with myself, my new AI personality generated inside Insmed, which is supposed to mirror the way I think, so that in a bizarre setting, I am actually asking myself about different ideas, speeches, business development, what have you, and it is supposed to give me my own thinking back in a more refined capacity. It is a little unsettling, but I will tell you it works pretty well. Just to make a finer point on it, the group that did this for me actually asked me to take a picture of my bookshelf, and they included all of those texts into my AI personality so that it would hopefully reflect the diverse set of interests I have, I guess.
Anyway, watching that unfold is really interesting in terms of decision making and strategic reflection, but the practical way we see AI being used at the earliest stages on research, the de-immunization of these therapeutic proteins in New Hampshire is driven by AI, and we have been doing that for several years from a professor we stole out of Dartmouth College and his colleague. We also use it in commercial settings and in clinical settings for patient finding, for optimizing call efforts. We have developed our own actual AI engine, which has access to all of Insmed's documents. It is based off of Claude, but it is hermetically sealed inside our company. I can go in and ask it, "How do we improve sales in years three through five?" I t will have access to all of our forecasting and cross-examine it and come back with ideas.
We are pretty heavy on the AI front. I am very proud of that. Mark Pellegrino, who is our CIO, has been a champion of that for many years. I think there is a lot more to come and a lot more benefit to be found there. But as we all know, that is assuming that AI does not wipe us all out in the next three years, which we were hearing about over the weekend. So who knows?
Yes. All right, last question. We have talked about increasing peak revenue. BRINSUPRI launch going very well. What are investors missing, or what is your message here at the end?
My message is that we are slow and steady up and to the right. We have just found our rhythm as a company, and we are executing commercially, we are executing clinically, and we are executing on the research front. I am super excited about where we are. Honestly, you get up here with different degrees of enthusiasm and caution for where a company you work at is in its life cycle. We are at the beginning of the strongest point of our growth cycle that we have ever been in, or frankly, ever could have imagined. This is a series of successful products that are going to be first or best in class that I think is just going to narrow benefit for at least the next 10 years.
Great. Thank you very much, Will.
Good.
Really appreciate it.
Pleasure.